Analyzing Survival Outcomes With Ixazomib-Rd in Relapsed/Refractory Multiple Myeloma
While treatment with ixazomib, lenalidomide, and dexamethasone (ixazomib-Rd) was shown to improve progression-free survival, recent long-term findings from the phase III TOURMALINE-MM1 trial published...
Comparing VTE Recurrence, Bleeding, and Death in Isolated Distal Versus Proximal DVT
Patients with isolated distal deep-vein thrombosis (DVT) and proximal DVT have similar long-term rates of venous thromboembolism (VTE) recurrence, bleeding, and death, according to...
Isatuximab Plus Carfilzomib and Dexamethasone Improves PFS in Relapsed/Refractory MM
Recent results suggest that in patients with relapsed multiple myeloma (MM), combination therapy consisting of carfilzomib and dexamethasone (Kd) plus isatuximab is associated with...
Ibrutinib Plus Venetoclax Shows Promise in Treatment-Naïve CLL
First-line combination therapy with ibrutinib and venetoclax was associated with higher rates of undetectable measurable residual disease (MRD), remission, and three-year progression-free survival (PFS)...
Exploring Venetoclax Plus Azacitidine in CMML and MPNs
The combination of the BCL2 inhibitor venetoclax and the hypomethylating agent azacitidine has been established as a standard of care for patients with acute...
Evaluating Seroprotection for Vaccine-Preventable Infections in CAR T-Cell Recipients
Patients with B-cell malignancies who achieve durable remissions following treatment with chimeric antigen receptor (CAR) T-cell therapies are at risk of long-term deficiencies in...
Are Physician Perceptions of Transfusions a Barrier to Hospice Enrollment for Patients With AML?
Patients with acute myeloid leukemia (AML) and their caregivers generally defer end-of-life (EOL) transfusion decisions to clinicians without participating in shared decision-making. This tendency...
Umbralisib Demonstrates Long-Term Safety and Clinical Activity in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma
Patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) have historically had poor long-term tolerance to phosphatidylinositol-3-kinase (PI3K) inhibitors. However, new study results published...
Rivaroxaban Reduces Risk of Cardiovascular Events in Patients With Atrial Fibrillation on Hemodialysis
Compared with vitamin K antagonists (VKAs), direct oral anticoagulants (DOACs) are associated with a superior risk-benefit profile in patients with normal renal function or...
Comparing Real-World Versus Clinical Trial Outcomes for Acute Promyelocytic Leukemia
A recent study published in Leukemia & Lymphoma examined one-month mortality and overall survival (OS) data of patients diagnosed with acute promyelocytic leukemia (APL)...
Current Issue
August 2021 Volume 7 Issue 10
This issue explores hematologic conditions in athletes, blue top tube shortages, and more.